Integra Lifesciences Holdings Operating Expenses Growth & History (IART)
Integra Lifesciences Holdings's operating expenses was $2.13B for fiscal 2025.
View full Integra Lifesciences Holdings company overviewIntegra Lifesciences Holdings annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.13B | $546.5M | +34.54% |
| 2024 | 2024-12-31 | $1.58B | $152.1M | +10.63% |
| 2023 | 2023-12-31 | $1.43B | $111.3M | +8.44% |
| 2022 | 2022-12-31 | $1.32B | −$26.5M | −1.97% |
| 2021 | 2021-12-31 | $1.35B | $124.7M | +10.22% |
| 2020 | 2020-12-31 | $1.22B | −$203.3M | −14.28% |
| 2019 | 2019-12-31 | $1.42B | $62.4M | +4.58% |
| 2018 | 2018-12-31 | $1.36B | $218.0M | +19.07% |
| 2017 | 2017-12-31 | $1.14B | $266.7M | +30.42% |
| 2016 | 2016-12-31 | $876.7M | $400.1M | +83.95% |
| 2015 | 2015-12-31 | $476.6M | $50.7M | +11.90% |
| 2014 | 2014-12-31 | $425.9M | $44.0M | +11.52% |
| 2013 | 2013-12-31 | $381.9M | −$60.8M | −13.72% |
| 2012 | 2012-12-31 | $442.7M | $16.6M | +3.91% |
| 2011 | 2011-12-31 | $426.0M | $60.8M | +16.66% |
| 2010 | 2010-12-31 | $365.2M | $25.4M | +7.49% |
| 2009 | 2009-12-31 | $339.7M | −$14.6M | −4.13% |
| 2008 | 2008-12-31 | $354.4M | — | — |
Integra Lifesciences Holdings quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $399.5M | −$528.8M | −56.97% |
| Q1 2026 | 2026-03-31 | $380.4M | −$17.7M | −4.45% |
| Q4 2025 | 2025-12-31 | $411.9M | $4.9M | +1.20% |
| Q3 2025 | 2025-09-30 | $390.3M | $1.3M | +0.34% |
| Q2 2025 | 2025-06-30 | $928.3M | $507.1M | +120.39% |
| Q1 2025 | 2025-03-31 | $398.1M | $33.2M | +9.11% |
| Q4 2024 | 2024-12-31 | $407.0M | $46.0M | +12.75% |
| Q3 2024 | 2024-09-30 | $389.0M | $33.2M | +9.32% |
| Q2 2024 | 2024-06-30 | $421.2M | $52.4M | +14.22% |
| Q1 2024 | 2024-03-31 | $364.9M | $20.4M | +5.94% |
| Q4 2023 | 2023-12-31 | $361.0M | $30.8M | +9.33% |
| Q3 2023 | 2023-09-30 | $355.8M | $35.7M | +11.15% |
| Q2 2023 | 2023-06-30 | $368.8M | $30.8M | +9.12% |
| Q1 2023 | 2023-03-31 | $344.5M | $14.0M | +4.23% |
| Q4 2022 | 2022-12-31 | $330.2M | −$17.1M | −4.93% |
| Q3 2022 | 2022-09-30 | $320.1M | −$10.3M | −3.11% |
| Q2 2022 | 2022-06-30 | $337.9M | −$190,000 | −0.06% |
| Q1 2022 | 2022-03-31 | $330.5M | $1.1M | +0.34% |
| Q4 2021 | 2021-12-31 | $347.3M | $11.3M | +3.36% |
| Q3 2021 | 2021-09-30 | $330.4M | $17.7M | +5.67% |
| Q2 2021 | 2021-06-30 | $338.1M | $93.6M | +38.25% |
| Q1 2021 | 2021-03-31 | $329.4M | $2.1M | +0.65% |
| Q4 2020 | 2020-12-31 | $336.0M | −$23.0M | −6.42% |
| Q3 2020 | 2020-09-30 | $312.7M | −$87.0M | −21.77% |
| Q2 2020 | 2020-06-30 | $244.6M | −$93.1M | −27.57% |
| Q1 2020 | 2020-03-31 | $327.2M | −$161,000 | −0.05% |
| Q4 2019 | 2019-12-31 | $359.0M | $9.8M | +2.82% |
| Q3 2019 | 2019-09-30 | $399.7M | $57.5M | +16.81% |
| Q2 2019 | 2019-06-30 | $337.7M | −$870,000 | −0.26% |
| Q1 2019 | 2019-03-31 | $327.4M | −$4.1M | −1.24% |
| Q4 2018 | 2018-12-31 | $349.2M | −$12.2M | −3.37% |
| Q3 2018 | 2018-09-30 | $342.2M | $74.0M | +27.59% |
| Q2 2018 | 2018-06-30 | $338.6M | $73.4M | +27.67% |
| Q1 2018 | 2018-03-31 | $331.5M | $82.8M | +33.31% |
| Q4 2017 | 2017-12-31 | $361.4M | $146.5M | +68.17% |
| Q3 2017 | 2017-09-30 | $268.2M | $48.0M | +21.77% |
| Q2 2017 | 2017-06-30 | $265.2M | $38.2M | +16.85% |
| Q1 2017 | 2017-03-31 | $248.7M | $34.0M | +15.84% |
| Q4 2016 | 2016-12-31 | $214.9M | $87.7M | +69.01% |
| Q3 2016 | 2016-09-30 | $220.2M | $3.9M | +1.79% |
| Q2 2016 | 2016-06-30 | $226.9M | $38.6M | +20.50% |
| Q1 2016 | 2016-03-31 | $214.7M | $33.4M | +18.41% |
| Q4 2015 | 2015-12-31 | $127.2M | $22.7M | +21.76% |
| Q3 2015 | 2015-09-30 | $216.4M | $36.0M | +19.93% |
| Q2 2015 | 2015-06-30 | $188.3M | −$30.6M | −13.99% |
| Q1 2015 | 2015-03-31 | $181.3M | −$25.0M | −12.13% |
| Q4 2014 | 2014-12-31 | $104.4M | $30.6M | +41.53% |
| Q3 2014 | 2014-09-30 | $180.4M | −$64.0M | −26.18% |
| Q2 2014 | 2014-06-30 | $219.0M | $19.0M | +9.48% |
| Q1 2014 | 2014-03-31 | $206.3M | $7.5M | +3.76% |
| Q4 2013 | 2013-12-31 | $73.8M | $39.4M | +114.51% |
| Q3 2013 | 2013-09-30 | $244.4M | $54.0M | +28.39% |
| Q2 2013 | 2013-06-30 | $200.0M | $86.1M | +75.62% |
| Q1 2013 | 2013-03-31 | $198.8M | $94.8M | +91.12% |
| Q4 2012 | 2012-12-31 | $34.4M | −$78.6M | −69.57% |
| Q3 2012 | 2012-09-30 | $190.3M | $85.1M | +80.87% |
| Q2 2012 | 2012-06-30 | $113.9M | $1.4M | +1.23% |
| Q1 2012 | 2012-03-31 | $104.0M | $8.8M | +9.23% |
| Q4 2011 | 2011-12-31 | $113.0M | $14.4M | +14.56% |
| Q3 2011 | 2011-09-30 | $105.2M | $15.1M | +16.76% |
| Q2 2011 | 2011-06-30 | $112.5M | $22.9M | +25.62% |
| Q1 2011 | 2011-03-31 | $95.2M | $8.4M | +9.69% |
| Q4 2010 | 2010-12-31 | $98.7M | — | — |
| Q3 2010 | 2010-09-30 | $90.1M | $4.7M | +5.49% |
| Q2 2010 | 2010-06-30 | $89.6M | $7.5M | +9.19% |
| Q1 2010 | 2010-03-31 | $86.8M | — | — |
| Q3 2009 | 2009-09-30 | $85.4M | — | — |
| Q2 2009 | 2009-06-30 | $82.0M | — | — |
Integra Lifesciences Holdings operating expenses trends
Over the last five fiscal years, Integra Lifesciences Holdings's operating expenses increased from $1.22B to $2.13B, a change of $908.1M. The latest reported quarter, Q2 2026, shows $399.5M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Integra Lifesciences Holdings source filings ↗